Maarten van der Doelen

Chapter 4

Table 2A. Baseline patient-reported outcomes on cancer-specific and bone metastases-related health-related quality of life and bone pain intensity.

Subgroup 1-3 injections (N=22) Mean (SD) 54.9 (27.8) 63.6 (24.6) 58.3 (33.2) 76.9 (20.4) 80.3 (22.8) 75.8 (33.2) 43.4 (28.5) 7.6 (13.3) 51.5 (35.2) 25.8 (29.0) 21.2 (24.2) 19.7 (30.3) 9.1 (23.4) 4.5 (11.7) 4.5 (11.7)

Subgroup 4-5 injections (N=23) Mean (SD) 58.3 (21.9) 72.2 (21.7) 62.3 (34.5) 73.6 (25.8) 76.1 (22.9) 77.5 (26.9) 34.3 (23.7) 13.8 (25.5) 38.4 (29.1) 15.9 (24.3) 18.8 (22.1) 18.8 (33.1) 4.3 (11.5) 5.8 (21.7) 8.7 (18.0)

Subgroup 6 injections (N=77) Mean (SD) 65.9 (16.6) 73.5 (22.0) 66.7 (29.2) 79.5 (20.2) 86.6 (17.1) 81.2 (21.7) 34.3 (21.7) 5.6 (13.9) 33.8 (27.6) 15.2 (25.1) 19.9 (25.5) 12.1 (23.5) 12.1 (21.6) 10.0 (26.0) 7.5 (18.5)

Total cohort (N=122) Mean (SD)

QLQ-30 functional scales a Global health status

62.5 (20.4) 71.5 (22.5) 64.3 (30.9) 77.9 (21.3) 83.5 (19.7) 79.5 (25.0) 36.0 (23.5) 7.5 (16.7) 37.8 (29.8) 17.2 (25.8) 19.9 (24.5) 14.8 (26.8) 10.1 (20.5) 8.2 (23.2) 7.2 (17.3)

Physical functioning

Role functioning

Emotional functioning Cognitive functioning

Social functioning

QLQ-30 symptom scales b Fatigue

Nausea/vomiting

Pain

Dyspnoea Insomnia

Appetite loss Constipation

Diarrhoea

Financial difficulties

BM-22 symptom scales b Painful sites

24.9 (16.6) 29.2 (24.1)

30.0 (19.7) 39.9 (27.6)

23.2 (16.8) 27.1 (22.9)

24.0 (15.5) 26.8 (22.9)

Pain characteristics

BM-22 functional scales a Functional interference

74.1 (20.7) 60.5 (18.2)

68.6 (24.0) 56.6 (21.8)

75.5 (19.9) 59.5 (21.1)

75.2 (20.0) 61.9 (16.1)

Psychosocial aspects

BPI-SF

Average pain score

3.4 (2.7)

4.2 (2.9)

3.3 (2.8)

3.1 (2.6)

Worst pain score

4.4 (3.2)

5.3 (3.3)

4.1 (3.1)

4.2 (3.2)

Mean health-related quality of life scores range from 0 to 100. a Functional and global scales: high scores indicate high level of functioning. b Symptom scales: high scores indicate high symptom burden.

98